WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007079351) NOVEL PRIME-BOOST COMBINATIONS OF ATTENUATED MYCOBACTERIUM
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/079351    International Application No.:    PCT/US2006/062143
Publication Date: 12.07.2007 International Filing Date: 15.12.2006
IPC:
A61K 39/04 (2006.01), C12Q 1/00 (2006.01), C12N 1/20 (2006.01)
Applicants: AERAS GLOBAL TB VACCINE FOUNDATION [US/US]; 1405 Research Boulevard, Rockville, MD 20850 (US) (For All Designated States Except US).
HONE, David, Michael [US/US]; (US) (For US Only).
SADOFF, Jerald, C. [US/US]; (US) (For US Only)
Inventors: HONE, David, Michael; (US).
SADOFF, Jerald, C.; (US)
Agent: WHITHAM, Michael, E.; Whitham, Curtis, Christofferson & Cook, P.C., 11491 Sunset Hills Road, Suite 340, Reston, VA 20190 (US)
Priority Data:
60/750,348 15.12.2005 US
Title (EN) NOVEL PRIME-BOOST COMBINATIONS OF ATTENUATED MYCOBACTERIUM
(FR) NOUVELLES COMBINAISONS DE PRIMO-IMMUNISATION/RAPPEL D'UNE MYCOBACTERIE ATTENUEE
Abstract: front page image
(EN)The present invention provides vaccine compositions for effective induction of both mucosal and systemic immunity to pathogenic Mycobacterium species. Vaccination protocols are provided in which both parenteral and mucosal vaccine formulations are administered to a host. The parenteral and mucosal formulations comprise live, attenuated Mycobacteria.
(FR)La présente invention concerne des compositions de vaccins visant à induire efficacement à la fois l'immunité des muqueuses et l'immunité systémique à l'espèce pathogène du genre Mycobacterium. L'invention concerne également des protocoles de vaccination selon lesquels des formulations de vaccins sont administrées à un hôte aussi bien par voie parentérale que par voie muqueuse. Les formulations s'administrant par voie parentérale et par voie muqueuse comprennent des mycobactéries vivantes, atténuées.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)